Abstract 2702
Background
As an ESMO designated centre of integrated oncology and palliative care it is important to have a range of skill mix and experience across the oncology nursing staff caring for these patients. Within a large acute general hospital, with patients on various wards across the hospital, challenges in achieving these aims may present themselves. The core ward consists of 14 single rooms; the non-core wards have a mix of 1, 2, 4 and 6 bedded rooms. This analysis aimed to assess the nature of hospitalisations and the associated outcomes for the whole cohort of patients on the associated ward.
Methods
All inpatients who were admitted or were pre-existing patients during the period of 8 weeks of analysis were assessed. The main features considered were the age, gender, cancer diagnosis, co-morbidities, reason for admission, and whether they returned to home, hospice or died in hospital. Whether patients were on the core chemotherapy ward or on outlying wards was assessed. Data from retrieved from the medical and nursing handover records and clinical information system of the Hospital.
Results
There were 44 patients (37.8%) cared for over the 50 admissions on the Core Therapeutic Ward staffed by oncology nurses over the 8 week period with the remainder cared for over the 92 admissions on outlying wards staffed by non-oncology nurses. The three most common reasons for admission (core/non-core ward) included symptom management with disease progression (42% vs 50%), anti-cancer therapy associated toxicities (18% vs 13%) & decline in activities of daily living (16% vs 15%). The most common oncology primary cancers included CNS (25% vs 20%), Lower GI (16% vs 15%) and GU (11.4% vs 13.5%). Disease related impaired cognition was the most common baseline co-morbidity present in each cohort (27.3%/12.2%). The patient discharge outcomes on each ward (onc/non-onc) were home (56.8%/85.1%), rehabilitation or long term care (10.1% vs 2.7%), hospice (6.8%/4.1%) and death (27.3%/8.1%) reflecting that less well patients tended to be cared for within the specialist ward.
Conclusions
Balancing the optimal location and nursing skill set is a challenge and remains an important focus and priority within a service ranging from high dose chemotherapy administration for curative intent to palliative and terminal care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont Hospital Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract